Rep. Robert Bresnahan, Jr. Purchases Shares of Bio-Techne Co. (NASDAQ:TECH)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Bio-Techne Co. (NASDAQ:TECH). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Bio-Techne Stock Down 2.0 %

TECH stock traded down $1.22 on Friday, reaching $58.73. 1,505,061 shares of the company traded hands, compared to its average volume of 1,111,228. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.94 and a quick ratio of 2.77. The firm has a fifty day simple moving average of $66.56 and a 200-day simple moving average of $71.45. Bio-Techne Co. has a one year low of $56.60 and a one year high of $85.57. The company has a market cap of $9.28 billion, a P/E ratio of 59.32, a price-to-earnings-growth ratio of 2.88 and a beta of 1.30.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. Research analysts anticipate that Bio-Techne Co. will post 1.67 earnings per share for the current year.

Bio-Techne Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Monday, February 17th were paid a $0.08 dividend. The ex-dividend date was Friday, February 14th. This represents a $0.32 annualized dividend and a dividend yield of 0.54%. Bio-Techne’s payout ratio is 32.32%.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TECH. Norges Bank acquired a new position in Bio-Techne during the fourth quarter worth about $137,301,000. Price T Rowe Associates Inc. MD increased its stake in Bio-Techne by 13.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,654,267 shares of the biotechnology company’s stock valued at $767,428,000 after purchasing an additional 1,229,954 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Bio-Techne during the third quarter worth $89,724,000. Raymond James Financial Inc. purchased a new stake in Bio-Techne during the fourth quarter worth $44,479,000. Finally, Select Equity Group L.P. grew its holdings in Bio-Techne by 26.9% in the fourth quarter. Select Equity Group L.P. now owns 2,335,359 shares of the biotechnology company’s stock valued at $168,216,000 after purchasing an additional 495,404 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TECH. Citigroup cut their price objective on Bio-Techne from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Robert W. Baird lowered Bio-Techne from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $88.00 to $68.00 in a report on Wednesday, February 19th. Evercore ISI initiated coverage on shares of Bio-Techne in a research note on Tuesday, March 18th. They set an “outperform” rating and a $75.00 price objective for the company. StockNews.com downgraded Bio-Techne from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Royal Bank of Canada upped their price objective on Bio-Techne from $79.00 to $80.00 and gave the company a “sector perform” rating in a research report on Thursday, February 6th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $81.25.

Insider Activity

In other news, Director Amy E. Herr sold 1,860 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $65.96, for a total transaction of $122,685.60. Following the transaction, the director now directly owns 1,976 shares in the company, valued at $130,336.96. This represents a 48.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kim Kelderman sold 13,392 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the transaction, the chief executive officer now directly owns 39,004 shares of the company’s stock, valued at $3,014,619.16. This trade represents a 25.56 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.